Day 1, Thursday, May 11th
08:30-10:00 ADCs: a new era in myeloma therapy
Pre-COMy Springer Healthcare IME CME Symposium supported by GSK
10:00-10:30 Coffee Break
10:30-10:45 COMy 2023 kick-off
10:45-12:15 Session 1: Latest updates in disease biology
12:15-13:00 Lunch Break
13:00-14:00 BCMA-Targeted Therapies – A New Combination Partner in Early Relapsed/Refractory Multiple Myeloma
Industry-supported Symposium by GSK
14:00-14:15 Technical Break
14:15-15:45 Session 2: Disease work-up and risk assessment
15:45-17:15 Session 3: Precursor conditions and related disorders – diagnosis and management
17:15-17:45 Coffee Break
17:45-19:15 Clinical utility of NGS-MRD in multiple myeloma
Industry-supported Symposium by Adaptive Biotechnologies
19:15-19:30 Technical Break
19:30-20:15 Session 4: Plenary lecture
Day 2, Friday, May 12th
08:00-08:30 Good Morning Breakfast
08:30-09:30 Let’s get real: Modern management of RRMM in older patients
Medthority CME Symposium supported by Takeda
09:30-09:40 Technical Break
09:40-10:10 The evolving role of alkylating agents in multiple myeloma; from the past and present to next generation
peptide drug conjugates
Industry-supported Presentation by Oncopeptides
10:10-11:25 Session 5: IMS: Impact on real life
11:25-11:50 Coffee Break
11:50-13:20 Session 6: Practical considerations in the management of myeloma
13:20-14:00 Lunch Break
14:00-15:00 We need a little controversy: fresh perspectives on cure in MM
Industry-supported Symposium by Janssen
15:00-15:15 Technical Break
15:15-16:30 Session 7: Treatment of relapsed myeloma – past, present and future
16:30-17:00 Coffee Break
17:00-18:00 Immunotherapy in multiple myeloma (MM): update on evolving use and therapy management
Industry-supported Symposium by Pfizer
18:00-18:15 Technical Break
18:15-19:15 Session 8: Plenary session I
19:15-20:00 Award Ceremony
Day 3, Saturday, May 13th
07:45-08:00 Good Morning Breakfast
08:00-09:00 Prediction of response to T-cell engagers
CME Symposium by a Pfizer educational grant
09:00-09:10 Technical Break
09:10-09:55 XPO-1 inhibitors in myeloma: where do we stand?
Industry-supported Symposium by Menarini-Stemline
09:55-11:25 Session 9: How I treat a frail myeloma
11:25-11:45 Coffee Break
11:45-12:45 Reform or Revolution? Modern Insights in MRD
Industry-supported Symposium by Sanofi
12:45-13:30 Lunch Break
13:30-15:00 Session 10: How I treat a young and fit myeloma patient
15:00-16:30 Session 11: How I treat a relapsed/refractory myeloma
16:30-16:45 Coffee Break
16:45-18:00 Treatment options in RRMM: expert controversies
Industry-supported Symposium by BMS
18:00-18:15 Technical Break
18:15-19:15 Session 12: Plenary session II
19:15-19:30 In-Person Conclusions
ONLINE Day 4, Sunday, May 14th
09:00-10:20 Session 13: Abstract communications I
10:20-11:20 Immunotherapy and bispecifics: a real-life case discussion
Virtual CME Symposium by a Pfizer educational grant
11:20-12:40 Session 14: Abstract communications II
12:40-13:10 From conventional alkylating agents to peptide-drug conjugates
Virtual CME Symposium by Oncopeptides
13:10-14:00 Final Panel Discussion: Immunotherapy for multiple myeloma: where to go from here?